Mutation-Directed Therapeutics for Neurofibromatosis Type I

Significant advances in biotechnology have led to the development of a number of different mutation-directed therapies. Some of these techniques have matured to a level that has allowed testing in clinical trials, but few have made it to approval by drug-regulatory bodies for the treatment of specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Leier, Andre, Bedwell, David M., Chen, Ann T., Dickson, George, Keeling, Kim M., Kesterson, Robert A., Korf, Bruce R., Marquez Lago, Tatiana T., Müller, Ulrich F., Popplewell, Linda, Zhou, Jiangbing, Wallis, Deeann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225739/
https://www.ncbi.nlm.nih.gov/pubmed/32408052
http://dx.doi.org/10.1016/j.omtn.2020.04.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225739/
https://www.ncbi.nlm.nih.gov/pubmed/32408052
http://dx.doi.org/10.1016/j.omtn.2020.04.012

Ejemplares similares